Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1313 | EMDR Wiki | 0.58 |
| drug2910 | Pioglitazone 30 mg Wiki | 0.58 |
| drug3070 | Prednisone tablet Wiki | 0.58 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D002055 | Burnout, Professional NIH | 0.19 |
| D000077062 | Burnout, Psychological NIH | 0.14 |
| D003924 | Diabetes Mellitus, Type 2 NIH | 0.14 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D003866 | Depressive Disorder NIH | 0.11 |
| D040921 | Stress Disorders, Traumatic NIH | 0.10 |
| D003920 | Diabetes Mellitus, NIH | 0.10 |
| D013313 | Stress Disorders, Post-Traumatic NIH | 0.10 |
| D003863 | Depression, NIH | 0.07 |
| D014777 | Virus Diseases NIH | 0.06 |
| D007239 | Infection NIH | 0.03 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.02 |
| D018352 | Coronavirus Infections NIH | 0.02 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0005978 | Type II diabetes mellitus HPO | 0.14 |
| HP:0000716 | Depressivity HPO | 0.11 |
| HP:0000819 | Diabetes mellitus HPO | 0.10 |
Navigate: Correlations HPO
There are 3 clinical trials
Coronavirus disease (COVID-2019) is a devastating viral illness that originated in Wuhan China in late 2019 and there are nearly 2 million confirmed cases. The mortality rate is approximately 5% of reported cases and over half of patients that require mechanical ventilation for respiratory failure. As the disease continues to spread, strategies for reducing duration of ventilator support in patients with COVID-19 could significantly reduce morbidity and mortality of these individuals and future patients requiring this severely limited life-saving resource. Methods to improve gas exchange and to reduce the inflammatory response in COVID-19 are desperately needed to save lives. The ketogenic diet is a high fat, low carbohydrate, adequate-protein diet that promotes metabolic ketosis (ketone body production) through hepatic metabolism of fatty acids. High fat, low carbohydrate diets have been shown to reduce duration of ventilator support and partial pressure carbon dioxide in patients with acute respiratory failure. In addition, metabolic ketosis reduces systemic inflammation. This mechanism could be leveraged to halt the cytokine storm characteristic of COVID-19 infection. The hypothesis of this study is that the administration of a ketogenic diet will improve gas exchange, reduce inflammation, and duration of mechanical ventilation. The plan is to enroll 15 intubated patients with COVID 19 infection and administer a 4:1 ketogenic formula during their intubation.
Description: PaCO2 is the partial pressure of carbon dioxide Units: millimeters of mercury
Measure: Change in the partial pressure of carbon dioxide (PaCO2) Time: Daily until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: Minute ventilation is the product of respiratory rate and tidal volume. Units: Liter per minute
Measure: Change in minute ventilation Time: every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: Respiratory system compliance measures the extent to which the lungs will expand. In a ventilated patient, compliance can be measured by dividing the delivered tidal volume by the [plateau pressure minus the total peep]. Units: liter/centimeter of water
Measure: Change in respiratory system compliance Time: every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: Driving pressure is a measure of the strain applied to the respiratory system and the risk of ventilator-induced lung injuries Driving pressure = Plateau pressure - Total Positive end-expiratory pressure (PEEP) Units: centimeter of water
Measure: Change in driving pressure Time: every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: Ventilator synchrony is the match between the patient's neural inspiratory time and the ventilator insufflation time
Measure: Change in ventilator synchrony Time: every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: Mean arterial pressure is the average pressure in a patient's arteries during one cardiac cycle. Mean arterial pressure = diastolic blood pressure +[1/3(systolic blood pressure - diastolic blood pressure)] Units: millimeter of mercury
Measure: Change in mean arterial pressure Time: every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: FiO2: Fraction of Inspired Oxygen Percentage of oxygen in the air mixture that is delivered to the patient. Units: %
Measure: Change in the fraction of inspired oxygen percentage of oxygen (FiO2) Time: every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: PaO2/FiO2 ratio is the ratio of arterial oxygen partial pressure (PaO2) to fractional inspired oxygen. Units: millimeter of mercury
Measure: Change in the partial pressure of carbon dioxide (PaO2) to the fraction of inspired oxygen percentage of oxygen (FiO2) ratio Time: every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: pH measures hydrogen ion activity. It is a conventional part of every arterial blood gas determination pH: no units.
Measure: Change in hydrogen ion activity (pH) Time: every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: Bicarbonate is a conventional part of every arterial blood gas determination Units: milliequivalents/Liter
Measure: Change in Bicarbonate (HCO3) Time: every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: Red blood cell count measure anemia or hypoglycemia. Units: cells per liter
Measure: Change in red blood cell count Time: every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: White blood cell count evaluates leukopenia or leukocytosis. Units: cells/liter
Measure: Change in white blood cell count Time: every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: White cell differential shows the amount of neutrophils, lymphocytes, basophils, eosinophils and may give some clue of the type of infection. Units: %
Measure: Change in white cell differential Time: every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: Hemoglobin is an indirect way to measure red blood cells. Units: gram/deciliter
Measure: Change in hemoglobin levels Time: every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: Hematocrit measures the volume percentage of red blood cells in blood. Units: %
Measure: Change in hematocrit Time: every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: Mean cell volume is a measure of the average volume of a red blood corpuscle. Units: femtoliters
Measure: Change in mean cell volume Time: every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: Mean cell hemoglobin is the average mass of hemoglobin per red blood cell in a sample of blood. Units: picograms
Measure: Change in mean cell hemoglobin Time: every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: Mean cell hemoglobin concentration is the average concentration of hemoglobin in a given volume of blood. Units: %
Measure: Change in mean cell hemoglobin concentration Time: every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: Platelet count measures the number of platelets in the blood and determines thrombocytopenia or thrombocytosis. Units: platelets/liter
Measure: Change in platelet count Time: every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: Red cell distribution width is a measure of the range of variation of red blood cell volume. Units: no units
Measure: Change in red cell distribution width Time: every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: Liver function test Units: gram/deciliter
Measure: Change in blood albumin level Time: every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: Liver function test Units: international units/liter
Measure: Change in serum alkaline phosphatase level Time: every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: Liver function test Units: international units/liter
Measure: Change in serum aspartate transaminase level Time: every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: Liver function test Units: international units/liters
Measure: Change in serum alanine aminotransferase level Time: every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: Kidney function test Units: milligram/deciliter
Measure: Change in blood urea nitrogen levels Time: every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: Kidney function test Units: milligram/deciliter
Measure: Change in serum calcium level Time: every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: Kidney function test Units: millimole/liter
Measure: Change in serum chloride level Time: every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: Kidney function test Units: millimole/liter
Measure: Change in serum potassium level Time: every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: Kidney function test Units: gram/deciliter
Measure: Change in serum creatinine level Time: every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: If the patient needs mechanical ventilation for a second time, this information will be collected.
Measure: Date patient is re-intubated or need mechanical ventilation for a second time Time: Up to 10 daysDescription: Time from intensive care unit admission until death or transfer to hospital bed.
Measure: Length of intensive care unit stay Time: Up to 10 daysDescription: Time from hospital admission to discharge from the hospital. This information will be collected.
Measure: The total hospital stay Time: Up to 10 daysDescription: Once the patient feels better and can leave the hospital, he/she will be discharged. The place of discharge (e.g. home, rehab facility, nursing home, etc), time and date will be collected.
Measure: Disposition at discharge Time: Up to 10 daysDescription: Heart rate: is the number of times a person's heart beats per minute
Measure: Change in heart rate Time: every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: Units: milligram
Measure: Change in the dosage of vasopressor medication Time: every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: Units: milligram/deciliter
Measure: Change in total blood cholesterol level Time: At baseline and every 24 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: Units: milligram/deciliter
Measure: Change in blood low-density lipoprotein level Time: At baseline and every 24 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: Units: milligram/deciliter
Measure: Change in blood high-density lipoprotein level Time: At baseline and every 24 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: Units: milligram/deciliter
Measure: Change in blood triglycerides level Time: At baseline and every 24 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: Glucose: sugar in blood. Units: millimole/liter
Measure: Change in blood glucose level Time: At baseline and every 24 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: Glucagon: hormone release by pancreas that increase concentration of glucose in blood. Units: nanogram/liter
Measure: Change in blood glucagon level Time: At baseline and every 24 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: Free fatty acids are fatty acids that are produced from triglycerides and are measure in blood.
Measure: Change in blood free fatty acids level Time: At baseline and every 24 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: Hormone that regulates glucose. Units: insulin units/liter
Measure: Change in blood insulin levels Time: At baseline and every 24 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: Leptin helps regulate and alter long-term food intake and energy expenditure. Units: nanogram/deciliter
Measure: Change in blood leptin levels Time: At baseline and every 24 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: Units: nanomole/liter
Measure: Change in blood insulin like growth factor 1 levels Time: At baseline and every 24 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: C-reactive protein is a protein made by the liver that measures inflammation (e.g. pancreatitis). Units: microgram/milliliter
Measure: Change in blood C-reactive protein levels Time: At baseline and every 24 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: Cytokines are signaling molecules that measure inflammation.
Measure: Change in blood interleukin-1β levels Time: At baseline and every 24 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: Cytokines are signaling molecules that measure inflammation.
Measure: Change in blood interleukin-6 levels Time: At baseline and every 24 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: Cytokines are signaling molecules that measure inflammation.
Measure: Change in blood interleukin-18 levels Time: At baseline and every 24 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: Cytokines are signaling molecules that measure inflammation.
Measure: Change in blood tumor necrosis factor alpha levels Time: At baseline and every 24 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: Chemokine that mediates inflammation.
Measure: Change in blood C-C motif chemokine ligand 2 (CCL2) levels Time: At baseline and every 24 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: Chemokine that mediates inflammation.
Measure: Change in blood C-C motif chemokine ligand 3 (CCL3) levels Time: At baseline and every 24 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: Chemokine that mediates inflammation.
Measure: Change in blood C-C motif chemokine ligand 4 (CCL4) levels Time: At baseline and every 24 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: Chemokine that mediates inflammation.
Measure: Change in blood B cell-attracting chemokine 1 (CXCL13) levels Time: At baseline and every 24 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: Ferritin stores iron inside of cells. Units: nanogram/milliliter
Measure: Change in blood ferritin levels Time: At baseline and every 24 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: Units: millimole/liter
Measure: Change in blood betahydroxybutyrate levels Time: At baseline and every 24 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysDescription: Units: millimole/liter
Measure: Change in blood urine acetoacetate levels Time: At baseline and every 24 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 daysStudy to compare the efficacy and safety of colchicine and glucocorticoids compared with the standard of treatment for moderate/severe COVID-19 in a fragile and vulnerable population, admitted to a geriatric hospital unit or in a transicional care center
Description: Number of patients that a short cycle of steroids (with prednisone 60 mg/d, in a single dose, for 3 consecutive days) administered together with colchicine (at doses of 0.5 to 1.5 mg/d, adjusted for weight and renal function, for 3 days and maintenance of 0.5 mg/d for 14 days in total) reduces mortality from COVID-19 in this population by at least 20%, compared to the approved standard treatment at participating centers.
Measure: Number of patients that a short cycle of steroids administered together with colchicine reduces mortality from COVID-19 Time: 28 daysDescription: Number and grade of adverse events at group of colchicine and glucocorticoids throughout the treatment and in the two weeks following treatment according to the incidence of: mild adverse event serious adverse events hypersensitivity (allergic) reactions of grade >=2
Measure: Number and grade of adverse events at group of colchicine and glucocorticoids throughout the treatment and in the two weeks following treatment Time: 28 daysDescription: Percentage of patients who stop medication due to adverse events.
Measure: Percentage of patients who stop medication due to adverse events. Time: 28 daysDescription: Severity of symptoms by COVID-19 in the two treatment arms (response to treatment to be assessed by overall survival at 28 days from the start of treatment).
Measure: Severity of symptoms by COVID-19 in the two treatment arms Time: 28 daysThe treatment with pioglitazone added to the standard treatment of patients with DM2 hospitalized for COVID-19 may produce a decrease in the number of patients who progress to a second phase of severe systemic inflammation.
Description: Number of patients receive pioglitazone treatment during their hospital stay who receive support with mechanical ventilation, enter the ICU and / or die.
Measure: Patients treated with pioglitazone, together with conventional treatment for COVID-19 infection, who during their admission evolve towards the need to receive support with mechanical ventilation, enter the ICU and / or die. Time: Through hospitalization period, an average of 10-20 days until hospital dischargeDescription: Proportion of patients who develop heart failure or adverse reaction associated with treatment.
Measure: Incidence of pioglitazone treatment-Emergent Adverse Events in patients with DM2 and symptomatic SARS-CoV-2 infection. Time: Everyday through hospitalization period, an average of 10-20 days until hospital dischargeDescription: Changes in this inflammation parameter: C-reactive protein (in mg/dl)
Measure: Biomarker analysis: systemic inflammation parameters during the administration of pioglitazone treatment. Time: Each 48 hours through hospitalization period, an average of 10-20 days until hospital dischargeDescription: Changes in this inflammation parameter: D-dimer (in μg/mL)
Measure: Biomarker analysis: systemic inflammation parameters during the administration of pioglitazone treatment. Time: Each 48 hours through hospitalization period, an average of 10-20 days until hospital dischargeDescription: Changes in this inflammation parameter: ferritin (in ng/mL)
Measure: Biomarker analysis: systemic inflammation parameters during the administration of pioglitazone treatment. Time: Each 48 hours through hospitalization period, an average of 10-20 days until hospital dischargeDescription: Changes in this inflammation parameter: creatine kinase (CK) (in mg/dL)
Measure: Biomarker analysis: systemic inflammation parameters during the administration of pioglitazone treatment. Time: Each 48 hours through hospitalization period, an average of 10-20 days until hospital dischargeDescription: Changes in this inflammation parameter: number of lymphocytes (in μL)
Measure: Biomarker analysis: systemic inflammation parameters during the administration of pioglitazone treatment. Time: Each 48 hours through hospitalization period, an average of 10-20 days until hospital dischargeAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports